Cantech Holding, Inc., formerly Reve Technologies, Inc., is a development-stage immunotherapeutic-based technology company. The Company is focused on commercialization of its proteins for the treatment of cancer and various infectious diseases. Its Irreversible Pepsin Fraction (IPF) is a therapeutic platform technology that can be used to facilitate a range of applications. IPF turns on the immune system to fight autoimmune diseases. IPF binds to thymus (T)-cells and turns on T helper cell type 1 (Th1) immune system responses that kill infected cells. The Company's lead compound is a suspension of IPF, which is indicated for the treatment of autoimmune diseases, such as cancer, cirrhosis and Hepatitis C. The Company's product, IMMUNE-THERAPEUTIC PROTEIN (ITP), is a therapeutic protein isolated from porsine pepsin, which is irreversible, modified, and fractionate to the sequence IPF. The ITP contains IPF as an active ingredient modulate with Vitamin-C ester.